iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first-in-class, investigational eyedrop formulation for pediatric myopia. The company’s lead programs comprise of novel proprietary products; IVMED-80 for keratoconus and IVMED-85 for myopia.
| Website | https://iveenamed.com/ |
| Revenue | $6 million |
| Employees | 8 (2 on RocketReach) |
| Founded | 2006 |
| Address | 391 Chipeta Way Ste I, Salt Lake City, Utah 84108, US |
| Phone | (801) 550-5863 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+4 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Transportation General, Biotechnology, Drug Delivery, Transportation, Science and Engineering, Clinical Trials, Health Care, Life Science, Medical Device |
| Keywords | Eye Medication, Ophthalmology, Vision Science, Myopia Treatment, Clinical Stage, Eye Health, Clinical Trials, Vision Care, Ocular Therapeutics, Eye Drops, New Drug Development, Drug Delivery, Regenerative Medicine, Medical Innovation, Ophthalmic Devices |
| Competitors | AbbVie, Regeneron, Alcon, Bausch + Lomb, Pfizer, Amgen, Santen, Viatris, Genentech, Viela Bio +47 more (view full list) |
| SIC | SIC Code 38 Companies, SIC Code 385 Companies |
| NAICS | NAICS Code 33 Companies, NAICS Code 339 Companies |
Looking for a particular iVeena employee's phone or email?
The iVeena annual revenue was $6 million in 2026.
Sarah Molokhia is the Co-founder and Chief Scientific Officer of iVeena.
2 people are employed at iVeena.
iVeena is based in Salt Lake City, Utah.
The NAICS codes for iVeena are [33, 339].
The SIC codes for iVeena are [38, 385].